KLK3 and prostate carcinoma: Studies have demonstrated that CPT blocks the interaction of LSD1 and androgen receptor (AR) at the promoter of the AR target gene, prostate-specific antigen (PSA), which demethylates H3K9me1/2, thereby inhibiting the transcriptional activity of PSA and suppressing the proliferation of AR-positive prostate cancer cells (Wu et al., 2012).